Ista petitions FDA over eye drug label

03/6/2011 | Reuters

Ista Pharmaceuticals sent a petition asking the FDA to reject any generic version's application for the withdrawn twice-daily eye medicine Xibrom that uses the original labeling. Ista said any generic's label should include a reference to the option of the once-daily dose.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care